Eterna Historical Balance Sheet

ERNA Stock

USD 0.52 0.01 1.89%

Trend analysis of Eterna Therapeutics balance sheet accounts such as Total Current Liabilities of 5.9 M or Total Stockholder Equity of 2.1 M provides information on Eterna Therapeutics' total assets, liabilities, and equity, which is the actual value of Eterna Therapeutics to its prevalent stockholders. By breaking down trends over time using Eterna Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Eterna Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Eterna Therapeutics is a good buy for the upcoming year.

Eterna Therapeutics Inventory

(813,105)

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.

About Eterna Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Eterna Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Eterna Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Eterna Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Eterna currently owns. An asset can also be divided into two categories, current and non-current.

Eterna Therapeutics Balance Sheet Chart

At present, Eterna Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 41.5 M, whereas Other Current Liabilities is forecasted to decline to about 837.9 K.

Total Assets Total Current Liabilities Total Stockholder Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Eterna Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Eterna Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Eterna Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Eterna Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Eterna Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Eterna Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.At present, Eterna Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 41.5 M, whereas Other Current Liabilities is forecasted to decline to about 837.9 K.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	1.1M	4.0M	882K	837.9K
Total Assets	32.4M	22.3M	49.1M	51.6M

Other Current Liab Total Assets

Eterna Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Non Current Assets Total	Non Currrent Assets Other	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Net Receivables	Good Will	Short Term Debt	Intangible Assets	Common Stock	Other Liab
Total Assets		-0.12	0.2	-0.26	0.92	-0.23	-0.3	0.94	0.08	0.33	0.96	0.44	0.88	0.88	-0.25	0.7	-0.71	0.37	0.5	0.5	-0.11	0.52	0.51	0.54	-0.22	0.61
Other Current Liab	-0.12		0.34	0.83	-0.31	0.97	0.33	-0.41	0.81	-0.4	-0.35	0.4	-0.37	-0.32	0.0	-0.44	0.16	0.02	0.28	0.28	0.43	-0.09	-0.39	-0.44	-0.19	0.03
Total Current Liabilities	0.2	0.34		0.15	0.04	0.33	-0.2	-0.02	0.49	0.17	0.13	0.43	0.17	0.09	0.55	0.12	-0.31	-0.09	0.17	0.17	0.36	-0.11	0.66	0.13	-0.34	0.4
Total Stockholder Equity	-0.26	0.83	0.15		-0.44	0.88	0.32	-0.55	0.63	-0.48	-0.52	0.37	-0.57	-0.5	0.03	-0.66	0.37	0.22	0.33	0.33	0.44	0.03	-0.56	-0.37	0.03	-0.21
Non Current Assets Total	0.92	-0.31	0.04	-0.44		-0.4	-0.32	0.95	-0.15	0.25	0.95	0.06	0.95	0.98	-0.39	0.87	-0.59	0.25	0.17	0.17	-0.32	0.49	0.53	0.58	-0.05	0.65
Non Currrent Assets Other	-0.23	0.97	0.33	0.88	-0.4		0.32	-0.51	0.78	-0.39	-0.46	0.34	-0.46	-0.4	0.07	-0.51	0.19	-0.05	0.21	0.21	0.45	-0.2	-0.42	-0.43	-0.23	0.01
Common Stock Shares Outstanding	-0.3	0.33	-0.2	0.32	-0.32	0.32		-0.33	0.27	-0.18	-0.36	-0.02	-0.32	-0.27	0.09	-0.25	0.25	-0.42	-0.18	-0.18	0.39	-0.31	-0.52	-0.82	-0.2	-0.1
Non Current Liabilities Total	0.94	-0.41	-0.02	-0.55	0.95	-0.51	-0.33		-0.19	0.42	0.99	0.22	0.92	0.92	-0.31	0.8	-0.69	0.28	0.32	0.32	-0.28	0.48	0.52	0.57	-0.15	0.54
Other Current Assets	0.08	0.81	0.49	0.63	-0.15	0.78	0.27	-0.19		-0.42	-0.12	0.54	-0.16	-0.13	0.36	-0.24	0.1	-0.2	0.27	0.27	0.48	-0.23	-0.12	-0.37	-0.22	-0.03
Other Stockholder Equity	0.33	-0.4	0.17	-0.48	0.25	-0.39	-0.18	0.42	-0.42		0.44	0.27	0.36	0.29	0.1	0.27	-0.83	0.07	0.29	0.29	0.07	0.08	0.45	0.31	-0.67	0.49
Total Liab	0.96	-0.35	0.13	-0.52	0.95	-0.46	-0.36	0.99	-0.12	0.44		0.28	0.94	0.93	-0.23	0.81	-0.73	0.26	0.34	0.34	-0.22	0.45	0.62	0.58	-0.2	0.6
Total Current Assets	0.44	0.4	0.43	0.37	0.06	0.34	-0.02	0.22	0.54	0.27	0.28		0.04	0.0	0.26	-0.23	-0.45	0.37	0.89	0.89	0.47	0.21	0.1	0.04	-0.44	0.07
Short Long Term Debt Total	0.88	-0.37	0.17	-0.57	0.95	-0.46	-0.32	0.92	-0.16	0.36	0.94	0.04		0.98	-0.29	0.95	-0.65	0.07	0.06	0.06	-0.24	0.34	0.69	0.53	-0.13	0.73
Property Plant And Equipment Net	0.88	-0.32	0.09	-0.5	0.98	-0.4	-0.27	0.92	-0.13	0.29	0.93	0.0	0.98		-0.32	0.94	-0.61	0.08	0.05	0.05	-0.26	0.35	0.59	0.51	-0.14	0.72
Current Deferred Revenue	-0.25	0.0	0.55	0.03	-0.39	0.07	0.09	-0.31	0.36	0.1	-0.23	0.26	-0.29	-0.32		-0.26	0.02	-0.4	-0.04	-0.04	0.32	-0.43	0.27	-0.14	-0.27	-0.25
Net Debt	0.7	-0.44	0.12	-0.66	0.87	-0.51	-0.25	0.8	-0.24	0.27	0.81	-0.23	0.95	0.94	-0.26		-0.49	-0.14	-0.24	-0.24	-0.28	0.18	0.68	0.44	-0.04	0.71
Retained Earnings	-0.71	0.16	-0.31	0.37	-0.59	0.19	0.25	-0.69	0.1	-0.83	-0.73	-0.45	-0.65	-0.61	0.02	-0.49		-0.13	-0.45	-0.45	-0.09	-0.14	-0.56	-0.42	0.74	-0.73
Accounts Payable	0.37	0.02	-0.09	0.22	0.25	-0.05	-0.42	0.28	-0.2	0.07	0.26	0.37	0.07	0.08	-0.4	-0.14	-0.13		0.7	0.7	-0.24	0.82	-0.07	0.56	0.29	-0.08
Cash	0.5	0.28	0.17	0.33	0.17	0.21	-0.18	0.32	0.27	0.29	0.34	0.89	0.06	0.05	-0.04	-0.24	-0.45	0.7		1.0	0.16	0.52	-0.03	0.23	-0.28	0.01
Cash And Short Term Investments	0.5	0.28	0.17	0.33	0.17	0.21	-0.18	0.32	0.27	0.29	0.34	0.89	0.06	0.05	-0.04	-0.24	-0.45	0.7	1.0		0.16	0.52	-0.03	0.23	-0.28	0.01
Net Receivables	-0.11	0.43	0.36	0.44	-0.32	0.45	0.39	-0.28	0.48	0.07	-0.22	0.47	-0.24	-0.26	0.32	-0.28	-0.09	-0.24	0.16	0.16		-0.5	-0.04	-0.38	-0.44	0.05
Good Will	0.52	-0.09	-0.11	0.03	0.49	-0.2	-0.31	0.48	-0.23	0.08	0.45	0.21	0.34	0.35	-0.43	0.18	-0.14	0.82	0.52	0.52	-0.5		0.03	0.48	0.36	0.1
Short Term Debt	0.51	-0.39	0.66	-0.56	0.53	-0.42	-0.52	0.52	-0.12	0.45	0.62	0.1	0.69	0.59	0.27	0.68	-0.56	-0.07	-0.03	-0.03	-0.04	0.03		0.54	-0.21	0.56
Intangible Assets	0.54	-0.44	0.13	-0.37	0.58	-0.43	-0.82	0.57	-0.37	0.31	0.58	0.04	0.53	0.51	-0.14	0.44	-0.42	0.56	0.23	0.23	-0.38	0.48	0.54		0.16	0.28
Common Stock	-0.22	-0.19	-0.34	0.03	-0.05	-0.23	-0.2	-0.15	-0.22	-0.67	-0.2	-0.44	-0.13	-0.14	-0.27	-0.04	0.74	0.29	-0.28	-0.28	-0.44	0.36	-0.21	0.16		-0.49
Other Liab	0.61	0.03	0.4	-0.21	0.65	0.01	-0.1	0.54	-0.03	0.49	0.6	0.07	0.73	0.72	-0.25	0.71	-0.73	-0.08	0.01	0.01	0.05	0.1	0.56	0.28	-0.49

Click cells to compare fundamentals

Eterna Therapeutics Account Relationship Matchups

Eterna Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	15.3M	12.9M	32.4M	22.3M	49.1M	51.6M
Other Current Liab	1.6M	966K	1.1M	4.0M	882K	837.9K
Total Current Liabilities	6.1M	3.1M	3.7M	7.7M	6.6M	5.9M
Total Stockholder Equity	5.1M	7.7M	6.5M	12.1M	2.2M	2.1M
Non Current Assets Total	9.2M	11.2M	13.7M	8.6M	39.5M	41.5M
Non Currrent Assets Other	2.3M	453K	522K	5.2M	120K	114K
Common Stock Shares Outstanding	71.9K	439.7K	2.2M	3.1M	5.3M	5.0M
Liabilities And Stockholders Equity	15.3M	12.9M	32.4M	22.3M	49.1M	51.6M
Non Current Liabilities Total	4.1M	2.1M	22.3M	2.5M	40.3M	42.3M
Other Current Assets	526K	102K	2.2M	1.3M	1.6M	2.3M
Other Stockholder Equity	136.3M	(245K)	166.2M	177.4M	189.2M	131.9M
Total Liab	10.2M	5.2M	25.9M	10.2M	46.9M	49.2M
Total Current Assets	6.1M	1.7M	18.8M	13.7M	9.6M	9.8M
Short Long Term Debt Total	6.1M	2.9M	2.7M	4.1M	41.8M	43.9M
Property Plant And Equipment Net	4.7M	4.9M	2.7M	1.3M	33.3M	34.9M
Current Deferred Revenue	460K	76K	1.2M	190K	218.5K	207.6K
Net Debt	2.8M	1.3M	(14.3M)	(7.3M)	34.3M	36.0M
Retained Earnings	(131.5M)	(18.1M)	(159.7M)	(165.3M)	(187.0M)	(196.3M)
Accounts Payable	835K	1.3M	1.8M	1.6M	1.1M	764.4K
Cash	3.3M	1.6M	17.0M	11.4M	7.6M	6.1M
Cash And Short Term Investments	3.3M	1.6M	17.0M	11.4M	7.6M	6.1M
Net Receivables	1.2M	116K	684K	951K	425K	678.2K
Good Will	1.0M	667K	696K	2.0M	2.4M	1.4M
Accumulated Other Comprehensive Income	200K	268K	245K	(1K)	(900.0)	(855.0)
Short Term Debt	3.2M	799K	852K	2.0M	4.4M	4.7M
Other Liab	930.4K	23K	48K	1.6M	1.9M	2.0M
Net Tangible Assets	7.7M	5.6M	23.5M	10.1M	11.6M	12.1M
Other Assets	7.3M	6.4M	1K	5.2M	4.7M	4.2M
Property Plant Equipment	653.8K	2.7M	3.2M	1.3M	1.5M	1.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:

How To Invest In Eterna

Details

Is Eterna Stock a good investment?

Details

What is Eterna Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.

You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(8.31)

Revenue Per Share

0.03

Return On Assets

(0.29)

Return On Equity

(11.54)

The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eterna Historical Balance Sheet

Eterna Therapeutics Inventory

(813,105)

About Eterna Balance Sheet Analysis

Eterna Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Eterna Therapeutics balance sheet Correlations

Eterna Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eterna Therapeutics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 0.99	Non Current Liabilities Total
Property Plant And Equipment Net	+ 0.98	Non Current Assets Total
Property Plant And Equipment Net	+ 0.98	Short Long Term Debt Total
Non Currrent Assets Other	+ 0.97	Other Current Liab
Total Liab	+ 0.96	Total Assets

Retained Earnings	- 0.83	Other Stockholder Equity
Intangible Assets	- 0.82	Common Stock Shares Outstanding
Other Liab	- 0.73	Retained Earnings
Retained Earnings	- 0.73	Total Liab
Retained Earnings	- 0.71	Total Assets
Retained Earnings	- 0.69	Non Current Liabilities Total